System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Roman Rouzier is an expert in Oncology at Centre François Baclesse (France). As of October 2026, ScienceLeadR ranks Roman Rouzier in the top 1% of experts worldwide for Breast Neoplasms, Breast Diseases and Genital Neoplasms, Female. Roman Rouzier has authored 638 publications, the most recent in 2026, and is an investigator in 16 clinical trials, 4 of them ongoing. SLR score: 1,926 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Roman Rouzier Centre François Baclesse France
1 926 ScienceLeadR Reputation 1926

Unlock

Register Login
Network Map

Oncology

Subspecialties: Gynecology - Surgery

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2000 - 2026
Source: PubMed

Centre Francois Baclesse

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 638

Citations

Citations: 22 811 1st author: 69 Last author: 130 Unique author: 4

Main journals

Bull Cancer 38
Cancer Res 33
J Clin Oncol 31
Ann Oncol 26
Gynecol Obstet Fertil 26

Best Journals

Ann Oncol 5
J Clin Oncol 3
Lancet Oncol 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Advanced high-grade serous ovarian cancer treated with intensive cytoreductive surgery and chemotherapy: prognostic impact of lymph node involvement: analysis of the French national ESME-Unicancer database.
PMID 42013623 — cytoreduction surgical procedures, lymph nodes, ovary, neoplasms, drug therapy, lymph, ovarian neoplasms, therapeutics, dissection, prognosis, chemotherapy		Eur J Surg Oncol20260
Digital illiteracy and access to remote patient monitoring in oncology: a multicentre study of healthcare providers' perceptions and patient-reported digital literacy.
PMID 42005927 — bias, monitoring, ambulatory, breast neoplasms, perception, health personnel, literacy		EClinicalMedicine20260
Comparison of sentinel lymph node mapping with comprehensive lymphadenectomy in p53-mutated endometrial cancer: a prospective, multi-center, non-inferiority, open-label, de-escalation, randomized, controlled trial (Study Protocol - SENTIMETREP53).
PMID 41796475 — lymph nodes, tomography, lymph node excision, positron-emission tomography, genital neoplasms, female, neoplasms, multiple chronic conditions, classification, sentinel lymph node, positron emission tomography computed tomography, genes, p53, lymph, morbidity, therapeutics, mutation, endometrial neoplasms		Int J Gynecol Cancer20260
Editorial-A Milestone in the Technological Development of Hadrontherapy, in FranceHadrontherapy, cryogenic cyclotron.
PMID 41510221 — cyclotrons		Int J Part Ther20250
Benefit of adding Cureety Techcare telemonitoring to usual care during injectable anticancer treatment: the OPTIMACURE multicentric French prospective randomized study.
PMID 41462241 — health services research, therapeutics		BMC Health Serv Res20250

Clinical Studies 16

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 5 Study Director: 1

By phase:

N/A 12
Phase 2 2
Phase 3 1
Phase 4 1

By status:

Completed 10
Recruiting 3
Not yet recruiting 2
Withdrawn 1

By type:

Interventional 10
Observational 6

By Monocentric/Multicentric:

monocentric 10
multicentric2to4 2
multicentric5to9 1
multicentricup10 3

Main Topics

Ongoing Clinical Trials

4 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
SENTInel Node Mapping Versus Comprehensive Lymphadenectomy in p53 Mutated Endometrial Cancer A Non Inferiority Randomized Trial
NCT06900582 — genes, lymph nodes, lymph node excision, ureter, neoplasms, sentinel lymph node, biopsy, arteries, genes, p53, lymph, tissues, ligaments, sentinel lymph node biopsy, indocyanine green, anatomy, iliac artery, mutation, dissection, endometrial neoplasms, cervix uteri		N/ANot yet recruiting2026
Risk reducing Strategies Including Fimbriectomy in Women With a Germline Mutation Predisposing to Ovarian or Pelvic Cancer
NCT06726330 — sterilization, menopause, premature, surgical procedures, operative, genetic predisposition to disease, ovary, cardiovascular diseases, neoplasms, cognitive dysfunction, sterilization, tubal, germ-line mutation, osteoporosis, ovarian neoplasms, patient preference, prophylactic surgical procedures, menopause, tissues, genes, brca1, salpingo-oophorectomy, mutation, pelvic neoplasms, fallopian tubes, ovariectomy, carcinoma, women		N/ANot yet recruiting2027
Collection of Endometrial Cancer derived Organoids to Evaluate the Efficacy of PARP Inhibitors PENDOR Pilot Study
NCT06603506 — pilot projects, pilots, poly(adp-ribose) polymerase inhibitors, blood, neoplasms, organoids, endometrial neoplasms		N/ARecruiting2024
HRD Tests for Ovarian cancER
NCT06152731 — recombination, genetic, poly(adp-ribose) polymerase inhibitors, homologous recombination, ovary, neoplasms, drug therapy, ovarian neoplasms, therapeutics, chemotherapy, carcinoma		Phase 2Recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS